Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG + bifidobacterium lactis BB12
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**lactobacillus rhamnosus GG + bifidobacterium lactis BB12** is an oral two-strain probiotic preparation comprising *Lacticaseibacillus rhamnosus* GG, formerly *Lactobacillus rhamnosus* GG and also known as LGG, and *Bifidobacterium animalis* subsp. *lactis* BB-12, commonly called *Bifidobacterium lactis* BB-12. It is a dietary probiotic blend rather than a single, globally standardized proprietary medicine. The live bacteria are intended to transiently modulate the gastrointestinal microbiota, support epithelial-barrier function, and influence local immune and metabolic signaling. The exact strain pair has been evaluated orally in randomized clinical studies in newly diagnosed type 1 diabetes and in children with autism spectrum disorder and gastrointestinal symptoms; the completed type 1 diabetes study found no significant preservation of residual beta-cell function. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8006832/))
- Other names
- BB-12 with LGGBB12 with LGGBB 12 with LGGBifidobacterium animalis subsp. lactis BB-12 + Lacticaseibacillus rhamnosus GGLGG + BB-12Lacticaseibacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12lactobacillus rhamnosus GG + bifidobacterium lactis BB12
Beyond the preview
Go deeper on lactobacillus rhamnosus GG + bifidobacterium lactis BB12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG + bifidobacterium lactis BB12.